Among inner-city children with asthma, daily inhaler adherence was “overestimated” by parents when compared with adherence ...
The Food and Drug Administration (FDA) has accepted for review the Biologics License Application (BLA) for depemokimab for asthma with type 2 inflammation and chronic rhinosinusitis with nasal polyps ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback